1. Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway
   Hui Ye et al, 2022, Frontiers in Pharmacology CrossRef
2. Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism
   Xiaoying Zhang et al, 2021, Frontiers in Pharmacology CrossRef
3. Energy metabolism disorders and potential therapeutic drugs in heart failure
   Yanan He et al, 2021, Acta Pharmaceutica Sinica B CrossRef
4. Role of Warburg Effect in Cardiovascular Diseases: A Potential Treatment Option
   Niken Puspa Kuspriyanti et al, 2021, The Open Cardiovascular Medicine Journal CrossRef
5. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling
   Pan-xia Wang et al, 2017, Acta Pharmacologica Sinica CrossRef
6. Reactivation of PPARα alleviates myocardial lipid accumulation and cardiac dysfunction by improving fatty acid β-oxidation in Dsg2-deficient arrhythmogenic cardiomyopathy
   Yubi Lin et al, 2023, Acta Pharmaceutica Sinica B CrossRef
7. Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
   Zirui Qiu et al, 2022, Cells CrossRef
8. Cardiac metabolism — A promising therapeutic target for heart failure
   Hannah Noordali et al, 2018, Pharmacology & Therapeutics CrossRef
9. Identification of the active compounds and drug targets of Chinese medicine in heart failure based on the PPARs-RXRα pathway
   Mingyan Shao et al, 2020, Journal of Ethnopharmacology CrossRef
10. Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits
    Pitchai Balakumar et al, 2019, Pharmacological Research CrossRef
11. Renal sympathetic denervation alleviates myocardial fibrosis following isoproterenol-induced heart failure
    Neng Wang et al, 2017, Molecular Medicine Reports CrossRef
12. Identification of energy metabolism-related biomarkers for risk prediction of heart failure patients using random forest algorithm
    Hao Chen et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
13. Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure
    Dianne M. Perez, 2021, International Journal of Molecular Sciences CrossRef
14. Downregulation of PTEN Promotes Autophagy via Concurrent Reduction in Apoptosis in Cardiac Hypertrophy in PPAR α−/− Mice
    Ritu Kumari et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
15. Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection
    Martino Deidda et al, 2019, International Journal of Molecular Sciences CrossRef
16. Exploring the protective effects of PNS on acute myocardial ischaemia-induced heart failure by Transcriptome analysis
    Xu Chen et al, 2021, Journal of Ethnopharmacology CrossRef
17. Effectual Endeavors of Silk Protein Sericin against Isoproterenol Induced Cardiac Toxicity and Hypertrophy in Wistar Rats
    Farogh Ahsan et al, 2022, Life CrossRef
18. Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance
    Evangelos Oikonomou et al, 2018, Heart Failure Reviews CrossRef
19. Brassica oleracea L. extract ameliorates isoproterenol-induced myocardial injury by regulating HIF-1α-mediated glycolysis
    Huiling Luan et al, 2024, Fitoterapia CrossRef
20. Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure
    N Dhyani et al, 2019, Human & Experimental Toxicology CrossRef